Akoya Biosciences, Inc. (AKYA)
Jul 8, 2025 - AKYA was delisted (reason: acquired by QTRX)
1.290
0.00 (0.00%)
Inactive · Last trade price on Jul 7, 2025
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Akoya Biosciences stock had an average target of 2.51, with a low estimate of 1.08 and a high estimate of 5.
Price Target: $2.51 (+94.57%)
Analyst Consensus: Hold
* Price targets were last updated on May 19, 2025.
Analyst Ratings
The average analyst rating for Akoya Biosciences stock from 7 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $1.8 → $1.08 | Hold | Maintains | $1.8 → $1.08 | -16.28% | May 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $3.5 → $1.8 | Hold | Maintains | $3.5 → $1.8 | +39.53% | Apr 29, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $2.4 → $1.65 | Hold | Maintains | $2.4 → $1.65 | +27.91% | Apr 14, 2025 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $3.5 → $1.8 | Buy → Hold | Downgrades | $3.5 → $1.8 | +39.53% | Mar 25, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $3.5 | Buy | Reiterates | $3.5 | +171.32% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
87.60M
from 81.67M
Increased by 7.26%
Revenue Next Year
97.62M
from 87.60M
Increased by 11.44%
EPS This Year
-0.76
from -1.12
EPS Next Year
-0.60
from -0.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 97.7M | 110.3M | 125.1M | ||
| Avg | 87.6M | 97.6M | 108.8M | ||
| Low | 76.0M | 89.1M | 95.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.6% | 25.9% | 28.1% | ||
| Avg | 7.3% | 11.4% | 11.4% | ||
| Low | -7.0% | 1.7% | -2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.46 | -0.36 | -0.40 | ||
| Avg | -0.76 | -0.60 | -0.47 | ||
| Low | -0.90 | -0.67 | -0.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.